Growth factors nsg28, nsg30, and nsg32
First Claim
Patent Images
1. An isolated polypeptide, said polypeptide comprising an amino acid sequence selected from the group consisting of:
- a) the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41;
b) a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID NO; and
c) a biologically active fragment of at least 50 contiguous amino acids of any of a) through b).
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed are NsG28, NsG30, NsG32 polypeptides, nucleic acids encoding NsG28, NsG30, NsG32 polypeptides, and antibodies that bind to NsG28, NsG30, NsG32 polypeptides as well as methods of making and using the same.
46 Citations
124 Claims
-
1. An isolated polypeptide, said polypeptide comprising an amino acid sequence selected from the group consisting of:
-
a) the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41; b) a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID NO; and c) a biologically active fragment of at least 50 contiguous amino acids of any of a) through b). - View Dependent Claims (2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 57, 58, 100, 101, 102)
-
-
6. (canceled)
-
24. An isolated nucleic acid molecule for medical use comprising a nucleotide sequence selected from the group consisting of:
-
a) a nucleotide sequence coding for a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41; b) a nucleotide sequence coding for a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID No.; c) a nucleotide sequence coding for a biologically active fragment of at least 50 contiguous amino acids of any of a) through b); d) a nucleotide sequence selected from the group consisting of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; e) a nucleotide sequence having at least 70% 90% sequence identity to a coding sequence selected from the group consisting of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; f) a nucleic acid sequence of at least 150 contiguous nucleotides of a coding sequence selected from the group consisting of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; g) the complement of a nucleic acid capable of hybridising hybridizing with a nucleic acid molecule having the sequence of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39 under conditions of high stringency; and h) the nucleic acid sequence of the complement of any of the above. - View Dependent Claims (25, 26, 27, 28, 31, 32, 33, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)
-
-
29. (canceled)
-
30. (canceled)
-
34. (canceled)
-
35. (canceled)
-
59. An implantable biocompatible cell device, the device comprising:
-
i) a semipermeable membrane permitting the diffusion of a polypeptide comprising an amino acid sequence selected from the group consisting of; A) the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41; B) a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID NO; and C) a biologically active fragment of at least 50 contiguous amino acids of any of A) through B) a virus, a vector or both; and ii) a core containing cells transformed or transduced with a vector comprising a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of; A) a nucleotide sequence coding for a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41; B) a nucleotide sequence coding for a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID No.; C) a nucleotide sequence coding for a biologically active fragment of at least 50 contiguous amino acids of any of A) through B); D) a nucleotide sequence selected from the group consisting of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; E) a nucleotide sequence having at least 90% sequence identity to a coding sequence selected from the group consisting of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; F) a nucleic acid sequence of at least 150 contiguous nucleotides of a coding sequence selected from the group consisting of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; G) the complement of a nucleic acid capable of hybridising hybridizing with a nucleic acid molecule having the sequence of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39 under conditions of high stringency; and H) the nucleic acid sequence of the complement of any of the above; or a packaging cell line capable of producing an infective virus particle, said virus particle comprising a Retroviridae derived genome comprising a 5′
retroviral LTR, a tRNA binding site, a packaging signal, a promoter operably linked to a polynucleotide sequence encoding a polypeptide comprising the amino acid sequence described in i). - View Dependent Claims (60, 61, 62, 63, 64, 65, 66, 67, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)
-
-
68-81. -81. (canceled)
-
98. A method of expanding a composition of mammalian cells, comprising administering to said composition a polypeptide of comprising an amino acid sequence selected from the group consisting of:
-
A) the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41; B) a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID NO; and C) a biologically active fragment of at least 50 contiguous amino acids of any of A) through B), or transducing/transfecting the cells with an expression vector comprising an isolated nucleic acid sequence, wherein the isolated nucleic acid sequence comprises a nucleotide sequence selected from the group consisting of; A) a nucleotide sequence coding for a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41; B) a nucleotide sequence coding for a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID No.;
;C) a nucleotide sequence coding for a biologically active fragment of at least 50 contiguous amino acids of any of A) through B); D) a nucleotide sequence selected from the group consisting of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; E) a nucleotide sequence having at least 90% sequence identity to a coding sequence selected from the group consisting of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; F) a nucleic acid sequence of at least 150 contiguous nucleotides of a coding sequence selected from the group consisting of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; G) the complement of a nucleic acid capable of hybridising hybridizing with a nucleic acid molecule having the sequence of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39 under conditions of high stringency; and H) the nucleic acid sequence of the complement of any of the above.
-
-
99. A method of differentiating a composition of mammalian cells, comprising administering to said composition a polypeptide of comprising an amino acid sequence selected from the group consisting of:
-
A) the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41; B) a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID NO; and C) a biologically active fragment of at least 50 contiguous amino acids of any of A) through B); or transducing/transfecting the cells with the an expression vector of comprising an isolated nucleic acid sequence, wherein the isolated nucleic acid sequence comprises a nucleotide sequence selected from the group consisting of; A) a nucleotide sequence coding for a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41; B) a nucleotide sequence coding for a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID No.; C) a nucleotide sequence coding for a biologically active fragment of at least 50 contiguous amino acids of any of A) through B); D) a nucleotide sequence selected from the group consisting of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; E) a nucleotide sequence having at least 90% sequence identity to a coding sequence selected from the group consisting of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; F) a nucleic acid sequence of at least 150 contiguous nucleotides of a coding sequence selected from the group consisting of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; G) the complement of a nucleic acid capable of hybridising hybridizing with a nucleic acid molecule having the sequence of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39 under conditions of high stringency, and H) the nucleic acid sequence of the complement of any of the above.
-
- 103. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 6, 7, 11, 12, 15, 16, 20, 21, 33, and 34, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15 of the amino acid residues in the sequence are so changed.
-
108. An isolated polynucleotide coding for a polypeptide comprising an amino acid sequence selected from the group consisting of:
-
A) the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41; B) a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID NO; C) a biologically active fragment of at least 50 contiguous amino acids of any of A) through B); and D) an amino acid sequence selected from the group consisting of SEQ ID No. 6, 7, 11, 12, 15, 16, 20, 21, 33, and 34, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15 of the amino acid residues in the sequence are so changed.
-
-
109. A method of preventing apoptosis in a neuronal cell, the method comprising contacting a neuronal cell with an affective amount of:
-
i) a polypeptide according to comprising an amino acid sequence selected from the group consisting of; A) the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, B) a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID NO; and C) a biologically active fragment of at least 50 contiguous amino acids of any of A) through B); ii) a nucleic acid according to sequence selected from the group consisting of; A) a nucleotide sequence coding for a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41; B) a nucleotide sequence coding for a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID No.; C) a nucleotide sequence coding for a biologically active fragment of at least 50 contiguous amino acids of any of A) through B); D) a nucleotide sequence selected from the group consisting of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; E) a nucleotide sequence having at least 90% sequence identity to a coding sequence selected from the group consisting of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; F) a nucleic acid sequence of at least 150 contiguous nucleotides of a coding sequence selected from the group consisting of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; G) the complement of a nucleic acid capable of hybridising hybridizing with a nucleic acid molecule having the sequence of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39 under conditions of high stringency and H) the nucleic acid sequence of the complement of any of the above; and iii) a vector according to comprising the nucleic acid sequence described in ii).
-
-
110. A method of treating a disorder characterized by neuronal apoptosis, the method comprising administering to a subject having a disorder characterized by neuronal apoptosis a therapeutically affective amount of:
-
i) a polypeptide according to comprising an amino acid sequence selected from the group consisting of; A) the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41; B) a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID NO; and C) a biologically active fragment of at least 50 contiguous amino acids of any of A) through B); ii) a nucleic acid according to sequence selected from the group consisting of; A) a nucleotide sequence coding for a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41; B) a nucleotide sequence coding for a sequence variant of the amino acid sequence selected from the group consisting of SEQ ID No. 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 36, 38, 40, and 41, wherein the variant has at least 90% sequence identity to said SEQ ID No. C) a nucleotide sequence coding for a biologically active fragment of at least 50 contiguous amino acids of any of A) through B); D) a nucleotide sequence selected from the group consisting of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; E) a nucleotide sequence having at least 90% sequence identity to a coding sequence selected from the group consisting of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; F) a nucleic acid sequence of at least 150 contiguous nucleotides of a coding sequence selected from the group consisting of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39; G) the complement of a nucleic acid capable of hybridising hybridizing with a nucleic acid molecule having the sequence of the coding sequence of SEQ ID No. 2, 8, 17, 22, 26, 30, 35, 37, and 39 under conditions of high stringency; and H) the nucleic acid sequence of the complement of any of the above; and iii) a vector according to comprising the nucleic acid sequence described in ii).
-
-
111. (canceled)
-
112. (canceled)
Specification